David Jonathan Powell Net Worth

The estimated Net Worth of David Jonathan Powell is at least $311 mil dollars as of 27 November 2020. David Powell owns over 43,282 units of Summit Therapeutics Inc stock worth over $311,285 and over the last 4 years David sold SMMT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Powell SMMT stock SEC Form 4 insiders trading

David has made over 2 trades of the Summit Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently David exercised 43,282 units of SMMT stock worth $79,639 on 27 November 2020.

The largest trade David's ever made was exercising 43,282 units of Summit Therapeutics Inc stock on 27 November 2020 worth over $79,639. On average, David trades about 36,857 units every 2 days since 2020. As of 27 November 2020 David still owns at least 13,713 units of Summit Therapeutics Inc stock.

You can see the complete history of David Powell stock trades at the bottom of the page.

What's David Powell's mailing address?

David's mailing address filed with the SEC is ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Summit Therapeutics Inc

Over the last 4 years, insiders at Summit Therapeutics Inc have traded over $0 worth of Summit Therapeutics Inc stock and bought 529,946,601 units worth $632,334,967 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, eManmeet Singh Soni. On average, Summit Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $751,966,329. The most recent stock trade was executed by Mahkam Zanganeh on 26 March 2024, trading 110,321 units of SMMT stock currently worth $411,497.

What does Summit Therapeutics Inc do?

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Complete history of David Powell stock trades at Summit Therapeutics Inc

Summit Therapeutics Inc executives and stock owners

Summit Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA,
  COO & Director
• Dr. Urte Gayko Ph.D.,
  Head of Regulatory Affairs, Quality Assurance & Safety and Director
• Robert W. Duggan,
  Co-CEO & Exec. Chairman
• Ankur Dhingra,
  Chief Financial Officer
• Divya Chari,
  Head of Global Clinical Operations
• Dr. Anne Heatherington,
  Head of Clinical Devel. and Quantitative Sciences
• Dr. Jonathon Tinsley,
  Chief Scientific Officer of DMD
• Campbell Hair,
  Head of HR?
• Dr. Elaine Stracker,
  Gen. Counsel?
• Dave Gancarz,
  Head of Investor Relations & Corp. Strategy
• Michelle Avery,
  Director of Investor Relations
• Prof. Dame Kay Davies DBE, FRS CBE,
  Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
• Jeff Huber,
  Director
• Camilla Graham,
  Chief Clinical Affairs Officer
• Manmeet Singh Soni,
  COO and CFO
• Mostafa Ronaghi,
  Director
• David Jonathan Powell,
  Chief Scientific Officer
• Luhua Wang,
  Director
• Ujwala Mahatme,
  Director
• Rainer M Erdtmann,
  Director
• Michael Paul Donaldson,
  Chief Financial Officer
• Kenneth A Clark,
  Director
• Jeffrey R Maranian,
  VP Corporate Controller
• Urte Gayko,
  Director
• Mahkam Zanganeh,
  Chief Executive Officer
• Ankur Dhingra,
  Chief Financial Officer
• Robert F. Booth,
  Director
• Yu Xia,
  Director
• Robert W Duggan,
  Co-Chief Executive Officer
• Bhaskar Anand,
  Chief Accounting Officer